Please assess the completion status of the following clinical trial:

Trial Title: A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 (or as required by local regulation).~* Histological or cytological confirmation of unresectable or metastatic solid tumor malignancy harboring a KRAS mutation.~* No more than 3 prior standard treatments appropriate for tumor type and stage of disease.~* ECOG performance status ≤ 1.~* Existence of measurable disease (according to Response evaluation criteria in solid tumors \[RECIST v1.1\] criteria).~* Subjects with asymptomatic CNS metastases and/or asymptomatic leptomeningeal carcinomatosis are eligible.~* Adequate organ function.~Exclusion Criteria:~* Major surgery within four weeks of the start of treatment.~* Previous other cancer requiring treatment within the previous two years.~* Clinically significant cardiovascular disease.~* Any of the following cardiac criteria:~* Mean resting corrected QT interval (QTc) \> 470 msec obtained from three ECGs and any factors that increase the risk of QTc prolongation or arrhythmic events~* Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG~* Known clinically significant active infections not controlled with systemic treatment (bacterial, fungal, viral including HIV positivity).~* Gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.~* Subjects being treated with or anticipating the need for treatment with strong CYP3A inhibitors or inducers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TPX-0005 + Trametinib (Type: EXPERIMENTAL): TPX-0005 + Trametinib Dose Escalation and Dose Expansion~Dose escalation: KRAS G12D mutant advanced solid tumors. Dose expansion: KRAS G12D locally advanced or metastatic NSCLC

Based on this trial design, predict the completion outcome and termination type (if applicable).